Beckley Psytech Acquires Eleusis Therapeutics Limited

Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II (SPKB)

January 20, 2022

Healthcare Services

Eleusis, a clinical-stage life sciences company developing IV-administered psilocybin-based drug candidate ELE-Psilo, signed a definitive business combination agreement to become a public company through a merger with SPAC Silver Spike Acquisition Corp. II. The combined company is expected to apply to list on Nasdaq under the symbol “ELEU,” with the deal expected to close in the second or third quarter of 2022, subject to customary approvals and conditions.

Beckley Waves (via NueCo Holdings PBC) Acquires Nue Life Health

October 26, 2023

Healthcare Services

Beckley Waves, a venture studio focused on building companies in the psychedelic ecosystem, has acquired the assets of Nue Life Health Inc. through a newly launched portfolio company, NueCo Holdings PBC. The acquisition will allow Beckley Waves to scale Nue Life's at-home ketamine-assisted therapy platform and expand access to underserved patients across the United States.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

EQT Private Equity to Acquire Zeus Company Inc

December 18, 2023

Medical Devices

EQT Private Equity (via its EQT X fund) has entered into an agreement to acquire Zeus Company, Inc., a global leader in advanced polymer components for medical devices, from the Tourville family. EQT plans to support Zeus with investments in production capacity, R&D, and operational improvements to accelerate growth in minimally invasive medical device markets.

Excelitas Technologies Acquires Phoseon Technology

February 15, 2023

Manufacturing

Excelitas Technologies Corp. completed the acquisition of Phoseon Technology, Inc. on February 15, 2023, adding Phoseon's LED-based UV curing and scientific illumination capabilities to its commercial business unit. Phoseon will continue to operate from its Hillsboro, Oregon headquarters and the deal expands Excelitas' product portfolio and R&D cooperation in UV LED solutions across industrial, medical device, electronics and life-sciences end markets.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.